

Welcome to the HCV Advocate’s DDW
Conference coverage. In an effort to best
serve our readership, we will post all the important and interesting abstracts
about HCV from the conference. While
attending the conference, we will update any abstracts that we personally cover at the conference. The
updated abstracts will be marked with the date that they have been updated and
posted. The other abstracts posted to
the web site are HCV related abstracts posted to www.ddw.org
that we have not been able to report on or update.
To locate specific abstracts on this page,
click on “Edit” at the top of your
browser (Microsoft Internet Explorer) and then on Find (on this page). In Netscape, click on “Search” and then on “Find
in This Page.” Simply type in a word or term and the search engine will list
the related abstracts.
Please click here
to view our fact sheet on reading and understanding an abstract.
Thank You,
Alan Franciscus
Editor-in-Chief
Hepatitis C
Clinical Hepatitis: Etiology, Diagnosis, and Natural
History-
Clinical Trials-
- ID# 1 – Antiviral Activity of
the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Patients With Chronic
Hepatitis C Virus: Preliminary Results From a Randomized, Double-Blind,
Placebo-Controlled, Ascending Multiple Dose Study
- ID# 4 – Valopicitabine (NM283),
Alone or with Peg-Interferon, Compared to Peg Interferon/Ribavirin (pegIFN/RBV) Retreatment in
Hepatitis C Patients with Prior Non-Response to PegIFN/RBV:
Week 24 Results
- Abstract
S1057 – Stronger Baseline HCV-Specific Immunity Is Associated With A
Higher Likelihood Of A Sustained Virological Response to Combination
Antiviral Therapy Of Chronic Hepatitis C (Updated
May 21, 2006)
- Abstract
S1058 – The impact of growth factors on Peg-Intron and Rebetol dose
reduction in patients treated for genotype 1 chronic hepatitis C (Updated May 21, 2006)
- Abstract
S1059 – Results of a Phase II dose ranging study of orally administered celgosivir as monotherapy in chronic hepatitis C
genotype-1 patients.
- Abstract
S1060 – Comparison of Daily Consensus Interferon versus Peginterferon alfa
2a Extended Therapy of 72 Weeks for Peginterferon / Ribavirin Relapse
Patients with Chronic Hepatitis C
- Abstract
S1061 – Higher Susceptibility of Peginterferon alfa 2a versus
Peginterferon alfa 2b Nonresponder Patients with
Chronic Hepatitis C to Retreatment with
Consensus Interferon Daily Dosing and Ribavirin
- Abstract
S1062 – Early viral response to CPG 10101, a new investigational antiviral
TLR9 agonist, in combination with pegylated interferon and/or ribavirin,
in prior relapse HCV responders: preliminary report of a randomized Phase
1 study
- Abstract
S1063 – The usefulness of sPECAM-1 and sVCAM-1 serum concentrations
measurement in the assessment of fibrosis, inflammatory activity and
antiviral therapy effectiveness in chronic hepatitis C
Complications of Liver Disease-
Epidemiology, Natural History, Diagnosis-
- Abstract 549 – High Prevalence of Hepatitis
C Virus Infection Among Russian Immigrants in the New York City
Metropolitan Area: Results of A Community-Based Screening Program
- Abstract 550 – Low Prevalence of Advanced
Fibrosis in African americans with chronic
hepatitis C and persistently normal serum ALT : The case for conservative
management
- Abstract 551 – Spontaneous Clearance of
Hepatitis C Virus Infection in African American Patients
- Abstract 552 – Prospective and independent
validation of the Lok index for prediction of
cirrhosis in patients with chronic hepatitis C: comparison with FibroScan, Fibrotest and
APRI
- Abstract 553 – Insulin resistance
influences hepatic inflammation in patients with chronic hepatitis C
- Abstract 554 – Diagnostic Liver Biopsy in
Patients wWith Advanced Fibrosis and Cirrhosis
- Abstract S1039 – Emerging Importance of Chronic
Hepatitis C in Asian Americans (Updated May 21, 2006)
- Abstract
S1040 – Initial Content Validation of a Disease-Targeted
Health-Related Quality of Life (HRQOL) Instrument in Chronic Hepatitis B
Virus (HBV) Infection: The HBQOL v1.0
- Abstract S1041 – Sero-prevalence
of hepatitis B and C in hospital personnel (Updated
May 21, 2006)
- Abstract S1042 – Prevalence and predictors of
high body mass index among native born and immigrant patients with chronic
hepatitis C in Canada (Updated May 21,
2006)
- Abstract S1043 – Polymorphisms in TLR7 and 8
affect severity of hepatic fibrosis and inflammation in individuals
infected with the hepatitis C virus from a single source. (Updated May 21, 2006)
- Abstract S1044 – Discordant IRF-3 Activation
and Hepatic Interferon-Stimulated Gene Expression Associates with Immune
Cell Infiltration in Chronic Hepatitis C
- Abstract S1045 – Can we predict advanced
fibrosis in daily practice based on common blood tests?
- Abstract S1046 – 13C-Methacetin Breath Test as
Quantitative Liver Function Test in Patients with Chronic Hepatitis C:
Continuous Automatic Molecular Correlation Spectroscopy Compared to
Isotopic Ratio Mass Spectrometry
- Abstract S1047 – 13C-Methacetin Breath Test by
Online Molecular Correlation Spectroscopy Compared to APRI and Liver
Biopsy for the Assessment of Fibrosis in Chronic Hepatitis C
- Abstract S1048 – Increased serum gammaglutamyltranspeptidase activity: a surrogate
marker of non alcoholic hepatic steatosis in chronic hepatitis C? (Updated May 21, 2006)
- Abstract S1049 – Sinusoidal Lymphocytosis as a Marker for Cryoglobulinemia in
Hepatitis C Liver Biopsies (Updated May 21,
2006)
- Abstract S1050 – Liver fibrosis and necroinflammatory activity in chronic hepatitis C
patients with persistently normal aminotransferases (Updated May 21, 2006)
- Abstract S1051 – High accuracy pre-treatment
prediction of Early Viral Response to combined pegIFN/ribavirin
therapy in HCV-infected patients by a novel method of gene expression
analysis: a preliminary study. (Updated
May 21, 2006)
- Abstract S1052 – MDM2 Promoter SNP309 is
Associated with Hepatocellular Carcinoma in Japanese Patients with Chronic
Hepatitis C (Updated May 21,
2006)
- Abstract S1054 – Comparative study concerning
the severity of hepatic lesions at the moment of diagnosis in patients
with Chronic B Viral Hepatitis vs. patients with Chronic C Viral Hepatitis
(Updated May 21, 2006)
- Abstract S1055 – Non-invasive Biomarkers of
Liver Fibrosis in Hemophilia Patients with Hepatitis C: Can You Avoid
Liver Biopsy? (Updated May 21,
2006)
- Abstract S1056 – Steatosis associated with
more severe fibrosis in in chronic hepatitis C.
- S1578. Eryrthopoeitin
Functions as a Cytoprotective Cytokine in
Primary Murine Hepatocytes.
- S1580. Beneficial effects of
the herbal medicine Inchin-ko-to on liver
function and regeneration after massive hepatectomy in rats. (Updated May 21, 2006)
- S1583. Green Tea Polyphenols Attenuate Acetaminophen Hepatotoxicity.
(Updated May 21, 2006)
- S1584. Protective effects of
glycyrrhizin on acetaminophen-induced hepatotoxicity in mice.
- S1585. 10 Cases of Severe
Hepatotoxicity Associated with Dietary Supplements from Herbalife® Products. (Updated
May 21, 2006)
- S1587. Drug-induced liver
injury in the outpatient hepatology clinic: frequency, causes and clinical
features.
- S1588. Liver Injury Related to
Complementary and Alternative Medicine (CAM): Compared with Conventional Medicine-related
Liver Injury.
- S1590. Excessive and Chronic
Ethanol Consumption Promotes Hepatic Carcinogenesis by Altering the Normal
Hepatocyte Homeostasis in the Liver of Diethylnitrosamine-initiated
Rats. (Updated May 21, 2006)
HCC–
Liver Disease–
Transplantation
Treatment–
HCV Treatment Issues and Early Drug Development–
Virology, Pathogenesis and Treatment–